CoChat

Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study

Open access
Lee, Jeeyun, Jung, Kyung Hae, Park, Young Suk, Ahn, Joong Bae, Shin, Sang Jun, Im, Seock-Ah, Oh, Do Youn, Shin, Dong Bok, Kim, Tae Won, Lee, Namsu, Byun, Jae Ho, Hong, Yong Sang, Park, Joon Oh, Park, Se Hoon, Lim, Ho Yeong, Kang, Won Ki · 2009 · Cancer Chemotherapy and Pharmacology
Cited by 77

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

BackgroundSimvastatin has demonstrated anti-tumor activity in preclinical studies via tumor cell senescence, anti-angiogenesis, and apoptosis. This phase II trial evaluated the efficacy and toxicity profile of conventional FOLFIRI chemotherapy plus simvastatin in metastatic colorectal cancer patients.MethodsPatients received irinotecan 180 mg/m2 as a 90-min infusion followed by leucovorin 200 mg/m2 in a 2-h infusion, and then 5-FU 400 mg/m2 bolus injection followed by 2,400 mg/m2 as a 46-h continuous infusion. Treatment cycles were repeated every 2 weeks until documented disease progression, unacceptable toxicity, or patient’s refusal. Simvastatin 40 mg tablet was given once daily per oral everyday during the period of chemotherapy without a rest.ResultsFrom October 2005 to June 2006, 49 patients were enrolled. The overall response rate (ORR) was 46.9% (95% CI, 31.0–58.8) by intent-to-treat analysis and 45.8% (95% CI, 33.3–62.8) by per-protocol analysis. There were one complete response (CR) and 22 partial responses (PRs). Both CR and PRs were confirmed at least 4 weeks later. The disease-control rate was 83.7% (95% CI, 73.4–94.0). The median follow-up duration was 25.6 months (range, 20.9–28.8 months). The median survival of all patients was 21.8 months (95% CI, 14.4, 29.2). The median TTP was 9.9 months (95% CI, 6.4, 13.3). No patients experienced additional adverse effect that was definitely caused by simvastatin drug therapy in this trial.ConclusionThe combination of simvastatin plus FOLFIRI was a feasible regimen with promising antitumor activity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00280-008-0913-5

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 77

Metadata

Authors
Lee, J., Jung, K. H., Park, Y. S., Ahn, J. B., Shin, S. J., Im, S.-A., Oh, D. Y., Shin, D. B., Kim, T. W., Lee, N., Byun, J. H., Hong, Y. S., Park, J. O., Park, S. H., Lim, H. Y., & Kang, W. K.
Venue
Cancer Chemotherapy and Pharmacology
Published
2009-01-24
Volume
64
Issue
4
Pages
657-663
ISSN
  • 0344-5704 (ISSN-L)
  • 1432-0843
OpenAlex
W1963581413
Cited by
77
References
5
FWCI
3.58
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. https://app.cochat.ai/papers/10.1007/s00280-008-0913-5
The paper
Lee, J., Jung, K. H., Park, Y. S., Ahn, J. B., Shin, S. J., Im, S.-A., Oh, D. Y., Shin, D. B., Kim, T. W., Lee, N., Byun, J. H., Hong, Y. S., Park, J. O., Park, S. H., Lim, H. Y., & Kang, W. K. (2009). Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-008-0913-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.